PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-10.68%
Negative net income growth while VET stands at 44.56%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-1.31%
Both reduce yoy D&A, with VET at -1.90%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-76.13%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
-112.62%
Both reduce yoy usage, with VET at -153.26%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-112.62%
Both reduce yoy usage, with VET at -100.00%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
104.45%
Some yoy increase while VET is negative at -108.22%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-10.38%
Both yoy CFO lines are negative, with VET at -61.75%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
15.81%
Lower CapEx growth vs. VET's 44.45%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-836.40%
We reduce yoy other investing while VET is 76.56%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-7.91%
We reduce yoy invests while VET stands at 50.88%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.